Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Scientific Reports|January 24, 2017
Genetic structure of Tibetan populations in Gansu revealed by forensic STR lociHong-Bing Yao, Chuan-Chao Wang, Jiang Wang, et al.
Iliver|May 13, 2026
Efficacy and safety of adjuvant transarterial chemoembolization in high-risk HCC after curative hepatectomy: a phase III RCT protocolChao-Man Huang, Shu-Chang Chen, Yi-He Yan, et al.
Journal of Human Genetics|April 22, 2020
Y-chromosome evidence confirmed the Kerei-Abakh origin of Aksay KazakhsShao-Qing Wen, Chang Sun, Dan-Lu Song, et al.
Scientific Reports|June 2, 2026
Progression-free survival as a potential surrogate endpoint for overall survival after conversion therapy for unresectable hepatocellular carcinoma (GUIDANCE008)Jin-Wei Wu, Da-Long Yang, Shu-Chang Chen, et al.
Hepatology (Baltimore, Md.)|February 5, 2025
Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in intermediate or advanced, but not early, stagesDa-Long Yang, Lin Ye, Fan-Jian Zeng, et al.
Liver Cancer|June 11, 2025
Survival Benefit of Hepatectomy after Complete or Partial Response to Conversion Therapy in Unresectable Hepatocellular Carcinoma (GUIDANCE003): A Multicenter StudyDa-Long Yang, Ning Peng, Jun-Liang Nong, et al.
Liver Cancer|January 19, 2026
Prognostic Usefulness of Clinical Complete Response after PD-1 Inhibitor-Based Combination Therapy for Unresectable Hepatocellular Carcinoma (GUIDANCE006)Liang Ma, Da-Long Yang, Teng-Meng Zhong, et al.
Liver Cancer|July 11, 2026
Real-World Efficacy and Safety of TACE Combined with Lenvatinib and PD-1 Inhibitor in Conversion Therapy for Unresectable Hepatocellular Carcinoma (GUIDANCE007): A Multicenter Retrospective StudyLin Ye, Guo-Xing Liu, Da-Long Yang, et al.
Communications Medicine|March 13, 2026
Neoadjuvant transarterial chemoembolization with tyrosine kinase and immune checkpoint inhibitors improves survival from resectable hepatocellular carcinoma in a multicenter, retrospective study (GUIDANCE002)Da-Long Yang, Chuang Qin, Ning Peng, et al.
JHEP Reports : Innovation in Hepatology|October 27, 2025
Prognostic value of radiological and pathological complete response following immune-based conversion therapy in patients with unresectable hepatocellular carcinoma (GUIDANCE004)Da-Long Yang, Yi-He Yan, Yong-Cheng Lai, et al.
Pageof 4